Dutasteride 5α-reductase Inhibitor in the Treatment of Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis

Dutasteride is a competitive inhibitor of the enzyme 5-alpha-reductase and commonly used to treat symptoms benign prostatic hyperplasia (BPH).
 Objective: determine efficacy safety dutasteride in terms indicators that are important clinical practice.
 Data sources. The literature was searched using search «prostate hyperplasia», hypertrophy», «dutasteride», «quality life», «adverse drug reaction». Articles were obtained from Embase, PubMed, Kokhranov Central Register Controlled Trials, with till December 2020.
 Study selection data recovery. Randomized controlled trials, quasi-randomized systematic reviews evaluating dutasteride, both monotherapy combination alpha-blockers for treatment men BPH included analysis. Indicators need prostate surgery, episodes acute urinary retention, discontinuation therapy due side effects, number patients who had serious mortality sexual dysfunction.
 Four studies involving 1,879 evaluated. All have shown significant retention higher than finasteride equal profiles.
 Conclusion. No statistically differences between two 5AR inhibitors profile found, based on this system review. This determines best cases surgery.